For example, studies on transgenic TRAF6-overexpressing mice show that MDS HSPCs can adapt to inflammation by upregulating A20. This favors the survival of MDS HSPCs while normal HSPCs are affected by inflammatory stress [89]. This evidence concerns the gene TRAF6 and myelodysplastic syndrome.